LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Portfolio Pulse from Vandana Singh
LuMind CEO Hampus Hillerstrom is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC:ESALY)/ Biogen Inc's (NASDAQ:BIIB) and Eli Lilly And Co's (NYSE:LLY) for people with Down syndrome. Hillerstrom is at odds with neurologists who recommend against immediate use, citing untested safety risks. Advocacy groups are lobbying Eisai and Lilly to conduct safety trials specifically for Down syndrome and for Medicare policy changes to ensure these individuals are not disqualified from treatment reimbursements.
October 10, 2023 | 4:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen Inc's Alzheimer's drug is being advocated for use in Down syndrome patients, despite safety concerns.
While the advocacy for the use of Biogen's drug in Down syndrome patients could potentially open up a new market, the safety concerns and the need for further trials could pose a risk.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Eisai Co Ltd's Alzheimer's drug is being advocated for use in Down syndrome patients, despite safety concerns.
While the advocacy for the use of Eisai's drug in Down syndrome patients could potentially open up a new market, the safety concerns and the need for further trials could pose a risk.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Eli Lilly And Co's Alzheimer's drug is being advocated for use in Down syndrome patients, despite safety concerns.
While the advocacy for the use of Eli Lilly's drug in Down syndrome patients could potentially open up a new market, the safety concerns and the need for further trials could pose a risk.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70